Cadrenal Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CVKD, updated each market day.
CVKD AI Sentiment
AI predicts Cadrenal Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Sector
Exchange
Market Cap
$12,458,880
Cap Tier
Employees
5
Headquarters
PONTE VEDRA, FL
Listed Since
Jan. 20, 2023
Website
CVKD Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CVKD Volatility
Cadrenal Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
